Send to:

Choose Destination
See comment in PubMed Commons below
Oncol Lett. 2011 Nov;2(6):1253-1256. Epub 2011 Jul 27.

A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer.

Author information

  • 1Department of Internal Medicine, Hallym Medical Center, Hallym University College of Medicine, Seoul 150-950, Republic of Korea.


This study was conducted to evaluate the efficacy and safety of the combination of mitomycin-C (MMC) and S-1 as third-line chemotherapy for patients with advanced colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens. Patients were recruited into the study from January 2009 and 10 patients were enrolled for 10 months. However, since no patients had shown a response by 10 months, the study was terminated early according to the protocol. MMC 7 mg/m(2) was administered intravenously on day 1 every 6 weeks in the first 4 cycles. S-1 was administered twice daily at 35 mg/m(2), within 1 h of meals on days 1-14. Following a rest for 7 days, S-1 was administered again on days 22-35, followed by a 7-day rest. A total of 14 cycles were delivered for 10 patients. All 10 patients were assessable for response. A total of 3 patients (30%) had stable disease and the remaining 7 showed disease progression. With a median follow-up of 7 months, the median overall survival was 10.5 months. Grade 3-4 myelotoxicities included neutropenia in two patients, anemia in two and thrombocytopenia in one. Grade 1-2 nausea and vomiting developed in 5 patients. One patient experienced grade 3 diarrhea. Grade 1-2 hand-foot syndrome occurred in 4 patients. In conclusion, the combination of MMC and S-1 as third-line chemotherapy in patients with advanced CRC appears to be well tolerated but has poor activity.

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk